Physician profile
Michael P Bey
NPI 1992777544
$26,636.08
in general payments reported to CMS, 2019-2025
68 companies · $3,978 in 2025
The $3,978 reported for 2025 was more than what 99% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,578 · 2020: $1,723 · 2021: $3,856 · 2022: $4,099 · 2023: $4,669 · 2024: $4,733 · 2025: $3,978.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $13K · Education: $227.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $13,153.72 |
| Education | $226.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $3,516.63 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $3,419.29 | 2020-2025 | Vraylar, Qulipta, Ubrelvy |
| Amgen INC. | $1,851.44 | 2019-2025 | Repatha, Otezla, Evenity |
| Novo Nordisk INC | $1,426.04 | 2019-2025 | Ozempic, Rybelsus |
| Pfizer INC. | $1,262.66 | 2019-2025 | |
| Lilly USA, LLC | $887.54 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $871.60 | 2021-2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $831.79 | 2019-2025 | Xifaxan, Trulance |
| Boehringer Ingelheim Pharmaceuticals, INC. | $721.21 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $705.50 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Phathom Pharmaceuticals, INC. | $655.28 | 2024-2025 | Voquezna |
| Merck Sharp & Dohme LLC | $649.43 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Novartis Pharmaceuticals Corporation | $637.88 | 2019-2025 | |
| Corcept Therapeutics | $628.06 | 2022-2025 | Korlym |
| Janssen Pharmaceuticals, INC | $563.09 | 2019-2025 | Spravato |
Show all 68 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $549.21 | 2021-2025 | |
| Amarin Pharma, INC. | $514.31 | 2019-2023 | |
| Sanofi-Aventis U.S. LLC | $475.38 | 2019-2023 | |
| Otsuka America Pharmaceutical, INC. | $452.97 | 2019-2025 | Rexulti |
| Bausch Health US, LLC | $431.60 | 2020-2024 | Aplenzin, Wellbutrin |
| Astellas Pharma US INC | $413.19 | 2019-2025 | Veozah, Myrbetriq |
| Allergan, INC. | $368.22 | 2019-2020 | |
| Esperion Therapeutics, INC. | $359.66 | 2021-2025 | Nexletol |
| Abbott Laboratories | $303.83 | 2021-2025 | Freestyle Libre 3 |
| Takeda Pharmaceuticals U.S.A., INC. | $257.61 | 2019-2025 | Vpriv, Trintellix |
| Evoke Pharma, INC. | $246.26 | 2023-2025 | Gimoti |
| Xeris Pharmaceuticals, INC. | $226.31 | 2025 | Recorlev, Gvoke Hypopen |
| Axsome Therapeutics, INC. | $222.60 | 2025 | Auvelity |
| Actelion Pharmaceuticals US, INC. | $214.45 | 2024-2025 | Uptravi, Opsumit |
| Azurity Pharmaceuticals, INC. | $209.45 | 2023-2025 | Edarbi, Alvesco, Azmiro |
| Lundbeck LLC | $208.54 | 2023-2025 | Rexulti |
| Sumitomo Pharma America, INC. | $204.26 | 2023-2025 | Gemtesa |
| Kowa Pharmaceuticals America, INC. | $190.10 | 2019-2025 | Zoryve, Livalo |
| Eisai INC. | $185.99 | 2020-2025 | |
| Vanda Pharmaceuticals INC. | $184.27 | 2025 | Fanapt |
| Arbor Pharmaceuticals, INC. | $175.34 | 2019-2021 | |
| Idorsia Pharmaceuticals US INC | $135.56 | 2023-2024 | Quviviq |
| Amneal Pharmaceuticals LLC | $125.99 | 2021-2025 | Unithroid |
| Qol Medical, LLC | $103.28 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $93.78 | 2023 | Austedo Xr |
| Sunovion Pharmaceuticals INC. | $93.35 | 2022 | |
| Paratek Pharmaceuticals, INC. | $80.34 | 2025 | Nuzyra, Xhance |
| Avanir Pharmaceuticals, INC. | $80.21 | 2022 | |
| Radius Health, INC. | $76.74 | 2022-2025 | Tymlos |
| Optinose US, INC. | $76.58 | 2024-2025 | |
| Biohaven Pharmaceuticals, INC. | $66.65 | 2020-2021 | |
| Horizon Therapeutics Plc | $60.14 | 2019-2021 | |
| E.R. Squibb & Sons, L.L.C. | $57.33 | 2019-2020 | |
| Biohaven Pharmaceutical Holding Company LTD. | $57.02 | 2022 | |
| Exact Sciences Corporation | $51.72 | 2024-2025 | Cologuard Collection Kit |
| Mylan Specialty L.P. | $47.41 | 2019-2023 | Yupelri |
| Seqirus USA INC | $41.29 | 2025 | Fluad, Flucelvax |
| Ardelyx, INC. | $38.94 | 2024 | Ibsrela |
| Daiichi Sankyo INC. | $38.16 | 2019 | |
| Dexcom, INC. | $35.54 | 2023 | Dexcom G6 Transmitter |
| Novum Pharma, LLC | $25.36 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $24.85 | 2019 | |
| Boston Scientific Corporation | $23.58 | 2025 | Watchman Access System |
| Collegium Pharmaceutical, INC. | $23.19 | 2023 | Xtampza |
| Scilex Pharmaceuticals INC. | $22.95 | 2022 | |
| Shire North American Group INC | $21.55 | 2019 | |
| Almatica Pharma LLC | $21.28 | 2022 | |
| Viatris Specialty LLC | $20.17 | 2025 | Yupelri |
| Dermira, INC. | $17.21 | 2020 | |
| Celgene Corporation | $15.33 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.96 | 2020 | |
| Corium, LLC | $13.52 | 2023 | Azstarys |
| Circassia INC. | $12.11 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Bey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.